A bill to be entitled

1

2

3

4

5

6 7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2324

25

26

27

28

An act relating to biomedical research; amending s. 20.435, F.S.; revising uses for funds credited to the Biomedical Research Trust Fund; amending s. 381.86, F.S.; providing that the Institutional Review Board within the Department of Health shall not review certain research within the jurisdiction of the Biomedical Research and Ethics Oversight Council; creating s. 381.99, F.S., the Florida Better Quality of Life and Biomedical Research Act; providing definitions; providing legislative findings; creating the Biomedical Research Advisory Council; providing for criteria, appointment, and terms of members; authorizing reimbursement for per diem and travel expenses; providing duties of the advisory council, including a report to the Governor, the President of the Senate, and the Speaker of the House of Representatives; requiring the Department of Health to provide administrative support; creating the Biomedical Research and Ethics Oversight Council to regulate research procedures and enforce ethical guidelines; providing for criteria, appointment, and terms of members; authorizing reimbursement for per diem and travel expenses; providing duties of the oversight council; providing for a grantsin-aid program for the purpose of conducting embryonic or human adult stem cell research; providing that grants-inaid shall be provided through funds in the Biomedical Research Trust Fund; restricting the use of such funds for research on certain stem cells; providing requirements

Page 1 of 13

CODING: Words stricken are deletions; words underlined are additions.

with respect to the disposition of human embryos following infertility treatment; requiring the Department of Health to develop and maintain on its Internet website a consent form for the donation of certain embryos; prohibiting purchase or sale of embryonic fetal tissue for research purposes; prohibiting certain acts relating to human reproductive cloning; providing penalties; providing an effective date.

Be It Enacted by the Legislature of the State of Florida:

- Section 1. Paragraph (h) of subsection (1) of section 20.435, Florida Statutes, is amended to read:
 - 20.435 Department of Health; trust funds. --
- (1) The following trust funds are hereby created, to be administered by the Department of Health:
 - (h) Biomedical Research Trust Fund.
- 1. Funds to be credited to the trust fund shall consist of funds deposited pursuant to ss. s. 215.5601, 288.955, and 381.99. Funds shall be used for the purposes of the James and Esther King Biomedical Research Program as specified in ss. 215.5602 and 288.955 and the purposes of the Florida Better Quality of Life and Biomedical Research Act as specified in s. 381.99. The trust fund is exempt from the service charges imposed by s. 215.20.
- 2. Notwithstanding the provisions of s. 216.301 and pursuant to s. 216.351, any balance in the trust fund at the end of any fiscal year shall remain in the trust fund at the end of

Page 2 of 13

the year and shall be available for carrying out the purposes of the trust fund. The department may invest these funds independently through the Chief Financial Officer or may negotiate a trust agreement with the State Board of Administration for the investment management of any balance in

- the trust fund.

 3. Notwithstanding s. 216.301 and pursuant to s. 216.351
 - 3. Notwithstanding s. 216.301 and pursuant to s. 216.351, any balance of any appropriation from the Biomedical Research Trust Fund which is not disbursed but which is obligated pursuant to contract or committed to be expended may be certified by the Governor for up to 3 years following the effective date of the original appropriation.
 - 4. The trust fund shall, unless terminated sooner, be terminated on July 1, 2008.
 - Section 2. Subsection (1) of section 381.86, Florida Statutes, is amended to read:
 - 381.86 Institutional Review Board. --

64

65

66

67

68

6970

71

72

73

74

75

76

77

78

79

80

81

- (1) The Institutional Review Board is created within the Department of Health in order to satisfy federal requirements under 45 C.F.R. part 46 and 21 C.F.R. parts 50 and 56 that an institutional review board review all biomedical and behavioral research on human subjects which is funded or supported in any manner by the department except for research within the jurisdiction of the Biomedical Research and Ethics Oversight Council, which shall be reviewed pursuant to the provisions of s. 381.99.
- Section 3. Section 381.99, Florida Statutes, is created to read:

381.99 Florida Better Quality of Life and Biomedical Research Act.--

- (1) SHORT TITLE. -- This section may be cited as the "Florida Better Quality of Life and Biomedical Research Act."
 - (2) DEFINITIONS.--As used in this section, the term:
- (a) "Adult stem cell" means an undifferentiated cell found among differentiated cells in a tissue or an organ that can renew itself and can differentiate to yield the major specialized cell types of the tissue or organ.
- (b) "Asexual reproduction" means reproduction not initiated by the union of oocyte and sperm.
- (c) "Embryonic stem cells" means cells obtained from the undifferentiated inner mass of an early stage embryo.
- (d) "Human reproductive cloning" means the practice of creating or attempting to create a human being by transferring the nucleus from a human cell into an egg cell from which the nucleus has been removed for the purpose of implanting the resulting product in a uterus or substitute for a uterus to initiate a pregnancy.
- (e) "In vitro fertilization" means a technique in which oocytes are fertilized by sperm outside of a woman's body resulting in organisms that are not genetically identical to any one existing human.
- (f) "Oocyte" means an immature egg cell of the human ovary.

Page 4 of 13

(3) LEGISLATIVE FINDINGS. -- The Legislature finds that:

- (a) An estimated 130 million Americans suffer from acute, chronic, and degenerative diseases and that there is enormous potential for lifesaving treatment and therapy as a result of recent advances in biomedical research.
- (b) Florida is unique among all states for its large projected net population increase within the next 20 years. This increase, in turn, raises significant health care concerns as a new, larger generation of retirees moves to Florida, resulting in a corresponding rise in the number of persons suffering from illnesses such as cancer, heart disease, Alzheimer's Disease, Parkinson's Disease, cerebral palsy, juvenile diabetes, atherosclerosis, amyotrophic lateral sclerosis, AIDS, spinal cord injuries, severe burns, osteoporosis, osteoarthritis, cystic fibrosis, muscular dystrophy, multiple sclerosis, macular degeneration, diabetic retinopathy, retinitis pigmentosa, cirrhosis of the liver, motor neuron disease, brain trauma, stroke, sickle cell anemia, and intestinal diseases.
- (c) In order to maintain a high quality of life for all Floridians, research into stem cell regenerative therapies and treatment should be supported to give hope and relief to the millions of citizens who suffer in silence from degenerative and crippling diseases.
- (d) To reduce the burden on the health care infrastructure, the state must shift its health care objectives from costly long-term maintenance toward prevention and cures.

(e) To bolster and advance Florida's burgeoning biotechnology industry, the state should provide funds and incentives for private research companies to work in the state.

- (f) The state should advance the goal of scientific and academic discourse in our universities and help bring its public and private universities to the forefront in biomedical research and technology.
- (g) It will benefit the economy of the state to create a wide array of new projects and high-paying jobs relating to biomedical research.
- (h) It will benefit the state to foster cooperation

 between the state's universities and private sector research in terms of jobs, resources, and academic discourse relating to biomedical research.
- (i) The public funds provided under this section are intended to spur innovation and development in Florida's biomedical technology sector, which will be used to treat debilitating chronic diseases.
- (4) BIOMEDICAL RESEARCH ADVISORY COUNCIL. -- There shall be established a Biomedical Research Advisory Council.
- (a) The advisory council shall consist of the Secretary of Health, who shall act as chair, and six additional members, who shall be appointed as follows:
- 1. Two persons appointed by the Governor, one of whom shall be an academic researcher in the field of stem cell research and one of whom shall have a background in bioethics.
- 2. One person appointed by the President of the Senate, who shall have a background in private sector stem cell funding

Page 6 of 13

HB 233 2006

167 and development and public sector biomedical research and funding.

- 3. One person appointed by the Speaker of the House of Representatives, who shall have a background in private sector stem cell funding and development and public sector biomedical research and funding.
- 4. One person appointed by the Minority Leader of the Senate, who shall have a background and experience in either public or private sector stem cell research and development.
- 5. One person appointed by the Minority Leader of the House of Representatives, who shall have a background and experience in business and financial investments.

180 Members shall serve for terms of 2 years each commencing on 181

168

169

170

171

172

173

174

175

176

177

178

179

182

183 184

185

186

187

188

189

190

191

192

193

194

- October 1, 2006. No member shall serve for more than two consecutive 2-year terms. All initial appointments must be made by October 1, 2006. The first meeting shall take place no later than November 1, 2006. Members shall meet at least twice annually, but no more than four times annually. Members shall serve without compensation but shall be reimbursed for per diem and travel expenses in accordance with s. 112.061.
- The members of the advisory council shall work to provide an environment fostering the advancement of embryonic and human adult stem cell research. The advisory council shall:
- 1. Develop a donated funds program for recommendation to the Secretary of Health, to encourage the development of funds other than state appropriations for embryonic and human adult stem cell research in the state.

Page 7 of 13

2. Examine and identify specific ways to improve and promote for-profit and not-for-profit embryonic and human adult stem cell and related research in the state, including, but not limited to, identifying both public and private funding sources for such research, maintaining existing embryonic and human adult stem cell related businesses, recruiting new embryonic and human adult stem cell related businesses to the state, and recruiting scientists and researchers in such fields to the state and state universities.

- 3. Develop a biomedical research grant program for recommendation to the Secretary Health, which shall provide grants-in-aid to eligible institutions for the advancement of embryonic or human adult stem cell research.
- 4. Develop, no later than December 1, 2006, an application for grants-in-aid under this section for recommendation to the Secretary of Health for the purpose of conducting embryonic or human adult stem cell research.
- 5. Receive applications from eligible institutions for grants-in-aid on and after December 1, 2006, and provide to the Secretary of Health recommended grant awards.
- 6. Monitor the stem cell research conducted by eligible institutions that receive such grants-in-aid.
- (c) The advisory council shall submit an annual progress report on the state of biomedical research in the state to the Florida Center for Universal Research to Eradicate Disease and to the Governor, the Secretary of Health, the President of the Senate, and the Speaker of the House of Representatives by June 30. The report must include:

Page 8 of 13

1. The amount of grants-in-aid awarded to eligible institutions from the Biomedical Research Trust Fund.

2. The recipients of such grants-in-aid.

- 3. The current status and progress of stem cell research in the state.
- 4. A list of research projects supported by grants-in-aid awarded under the program.
- 5. A list of publications in peer-reviewed journals involving research supported by grants-in-aid awarded under the program.
- 6. The total amount of biomedical research funding currently flowing into the state.
- 7. New grants for biomedical research that were funded based on research supported by grants-in-aid awarded under the program.
- 8. All other materials the council deems advisable to include.
- (d) Advisory council members shall disclose any conflict of interest or potential conflict of interest to the Secretary of Health.
- (e) The Department of Health shall provide administrative staff to assist the advisory council in developing the application for the grants-in-aid, reviewing such applications, making recommendations to the advisory council, preparing the written consent form described in paragraph (7)(b), and performing other administrative functions as the advisory council requires or as is deemed necessary.

(5) BIOMEDICAL RESEARCH AND ETHICS OVERSIGHT

COUNCIL.--There shall be established a Biomedical Research and

Ethics Oversight Council.

- (a) The oversight council shall consist of seven members, of which the Secretary of Health shall act as chair. The additional members shall be appointed as follows:
 - 1. Two persons appointed by the Governor.

- 2. One person appointed by the President of the Senate.
- 3. One person appointed by the Speaker of the House of Representatives.
- $\underline{\text{4. One person appointed by the Minority Leader of the}}$ Senate.
- 5. One person appointed by the Minority Leader of the House of Representatives.

All members must demonstrate knowledge and understanding of the ethical, medical, and scientific implications of embryonic and adult stem cell research and should also demonstrate knowledge of related fields, including, but not limited to, genetics, cellular biology, and embryology. At least three members shall have practical research experience in stem cell research or related fields. Members shall serve for terms of 4 years each commencing on October 1, 2006. No member shall serve for more than two consecutive 4-year terms. All initial appointments must be made by October 1, 2006. The first meeting shall take place no later than November 1, 2006. Members shall meet at least twice annually, but no more than four times annually. Members

shall serve without compensation but shall be reimbursed for per diem and travel expenses in accordance with s. 112.061.

2.79

- (b) The oversight council shall review all embryonic or human adult stem cell research which is funded or supported in any manner through the Biomedical Research Trust Fund to ensure the adherence to ethical and safety guidelines and procedures as laid out by federal ethical standards established by the United States Department of Health and Human Services.
 - (6) BIOMEDICAL RESEARCH TRUST FUND AND GRANTS-IN-AID.--
- (a) The Secretary of Health shall make grants-in-aid from the Biomedical Research Trust Fund in accordance with the provisions of this section.
- (b) The Department of Health shall require any applicant for a grant-in-aid under this section, for the purpose of conducting stem cell research, to submit a complete description of the applicant's organization, the applicant's plans for stem cell research, the applicant's proposed funding for such research from sources other than the state, and the applicant's proposed arrangements concerning financial benefits to the state as a result of any patent, royalty payment, or similar rights resulting from any stem cell research made possible by the awarding of such grant-in-aid. The Biomedical Research Advisory Council shall provide recommendations to the Secretary of Health with respect to awarding such grants-in-aid after considering recommendations from the Biomedical Research and Ethics Oversight Council.
- (c) Beginning with the 2006-2007 fiscal year, and for 10 consecutive years thereafter, not less than \$15 million shall be

Page 11 of 13

made available annually from the Biomedical Research Trust Fund for grants-in-aid to eligible institutions for the purpose of conducting embryonic or human adult stem cell research as directed by the Biomedical Research Advisory Council. Any balance of such amount not used for such grants-in-aid during a fiscal year shall be carried forward for the fiscal year next succeeding for such grants-in-aid.

- (7) FUNDING.--Funds provided under this section may only be used for research involving:
- (a) Human adult stem cells, including, but not limited to, adult stem cells derived from umbilical cord blood and bone marrow.
- (b) Human embryonic stem cells taken from donated leftover embryos from in vitro fertilization treatments that would otherwise be thrown away or destroyed.
- 1. A physician or other health care provider who is treating a patient for infertility shall provide the patient with timely, relevant, and appropriate information sufficient to allow the person to make an informed and voluntary choice regarding the disposition of any human embryos that remain following infertility treatment.
- 2. A person to whom information is provided pursuant to subparagraph 1. shall be presented with the options of storing any unused embryos, donating them to another person, donating the remaining embryos for research purposes, or selecting other means of disposition.
- 3. A person who elects to donate, for research purposes, any embryos remaining after receiving infertility treatment

Page 12 of 13

333 <u>shall provide written consent for that donation in a consent</u>
334 <u>form provided by the Department of Health and made available to</u>
335 the public on the department's Internet website.

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

- 4. A person may not knowingly, for material or financial gain, purchase, sell, or otherwise transfer or obtain, or promote the sale or transfer of, embryonic fetal tissue for research purposes pursuant to this section. Embryonic and adult stem cell material may only be donated for research purposes with the informed consent of the donor. A person who violates any provision of this subparagraph commits a felony of the second degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084.
 - (8) HUMAN REPRODUCTIVE CLONING; PROHIBITION; PENALTIES. --
 - (a) It is unlawful for any person to knowingly:
- 1. Perform or attempt to perform human reproductive cloning.
- 2. Participate or assist in an attempt to perform human reproductive cloning.
- 3. Ship or receive for any purpose an embryo produced by human reproductive cloning or any product derived from such embryo.
- (b) A person who violates any provision of paragraph (a) commits a felony of the second degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084.
- 357 Section 4. This act shall take effect July 1, 2006.